Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, June 18, 2019
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
Wednesday, May 29, 2019
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
Friday, May 17, 2019
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
Thursday, May 16, 2019
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
Friday, May 10, 2019
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
Thursday, May 9, 2019
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
Wednesday, May 8, 2019
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: